In Q1 2024, Eventide Asset Management held 104 positions worth $4.1B. They initiated 18 new positions and exited 61. Their largest holding was TT ($240.8M). Portfolio value grew +7.4% versus the prior quarter.
Frequently asked questions
What stocks did Eventide Asset Management own in Q1 2024?
Eventide Asset Management held 104 biotech stocks in their 13F portfolio in Q1 2024. Their top positions include TT, ZNTL, WCN, ROP, TTD. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Eventide Asset Management's portfolio worth in Q1 2024?
Eventide Asset Management's tracked biotech portfolio was worth $4.1B across 104 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
What did Eventide Asset Management buy in Q1 2024?
Eventide Asset Management initiated 18 new positions in Q1 2024, including CPRT, GTLB, VRNA, CELC, FDMT and 13 more. They also increased 39 existing positions.
What did Eventide Asset Management sell in Q1 2024?
Eventide Asset Management fully exited 61 positions in Q1 2024, including GTM, ZIP, WEC, SYY, SPT and 56 more. They also trimmed 23 existing positions.
Is Eventide Asset Management a biotech fund?
Values-based investment firm with significant biotech allocation. Kuruvilla—a physician, engineer, and PhD—leads a team that evaluates companies on both financial merit and alignment with ethical principles. Known for holding high-conviction biotech positions alongside broader healthcare and technology investments.
Want AI analysis, insider signals, and catalyst overlays for Eventide Asset Management?
View latest Eventide Asset Management portfolio →